



Exhibit 99.2
Prenetics

Prenetics[™]
Health. Reimagined.

Investor Presentation

September 2021

Disclaimer

This Presentation has been prepared by Artisan Acquisition Corp. ("SPAC") and Prenetics Group Limited (the "Company") in connection with a potential business combination involving SPAC and the Company (the "Transaction") and is preliminary in nature and solely for information purposes and must not be relied upon for any other purpose.

This Presentation does not constitute (i) an offer or invitation for the sale or purchase of the securities, assets or business described herein or a commitment of the Company or SPAC with respect to any of the foregoing or (ii) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction, and this Presentation shall not form the basis of any contract, commitment or investment decision and does not constitute either advice or a recommendation regarding any securities. Any offer to sell securities will be made only pursuant to a definitive subscription agreement and will be made in reliance on an exemption from registration under the Securities Act of 1933 (the "Securities Act") for offers and sales of securities that do not involve a public offering. This Presentation does not purport to contain all information that may be required or relevant to an evaluation of the Transaction, and you will be responsible for conducting any investigations and analysis that you deem appropriate and for seeking independent advice as to the legal, tax, accounting, financial, credit and other related advice with respect to the Transaction.

SPAC and the Company reserve the right to amend or replace this Presentation at any time but none of SPAC and the Company, their respective subsidiaries, affiliates, legal advisors, financial advisors or agents shall have any obligation to update or supplement any content set forth in this Presentation or otherwise provide any additional information to you in connection with the Transaction should circumstances, management's estimates or opinions change or any information provided in this Presentation become inaccurate.

Forward-Looking Statements

This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this Presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of the Company, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" or other similar expressions. All forward-looking statements are based upon current estimates and forecasts and reflect the views, assumptions, expectations, and opinions of SPAC and the Company as of the date of this Presentation, and are therefore subject to a number of factors, risks and uncertainties, some of which are not currently known to us. Some of these factors include, but are not limited to: the success of the new product or service offerings of the Company and its subsidiaries (the "Group"), the Group's ability to attract new and retain existing customers, competitive pressures in the industry in which the Group operates, the Group's ability to achieve profitability despite a history of losses, the Group's ability to implement its growth strategies and manage its growth, the Group's ability to meet consumer expectations, the Group's ability to produce accurate forecasts of its operating and financial results, the Group's internal controls, fluctuations in foreign currency exchange rates, the Group's ability to raise additional capital, media coverage of the Group, changes in the regulatory environments of the countries in which the Group operates, general economic conditions in the countries in which the Group operates, the Group's ability to attract and retain senior management and skilled employees, the success of the Group's strategic alliances and acquisitions, changes in the Group's relationship with its current customers, suppliers and service providers, disruptions to information technology systems and networks, the Group's ability to protect its brand and reputation, the Group's ability to protect its intellectual property, potential and future litigation that the Group may be involved in, taxes or other liabilities that may be incurred or required subsequent to, or in connection with, the consummation of the Transaction. The foregoing list of factors is not exhaustive. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

In light of these factors, risks and uncertainties, any estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of this Presentation and the "Risk Factors" section of the proxy statement/prospectus on Form F-4 relating to the Transaction, which is expected to be filed with the U.S. Securities and Exchange Commission ("SEC"), and other documents filed from time to time with SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. SPAC and the Company assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible to predict all risks, or assess the impact of all factors on the Company's business or the extent to which any factor, or combination of factors, may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. In addition, the analyses of SPAC and the Company contained herein are not, and do not purport to be, appraisals of the securities, assets or business of the Company, SPAC or any other entity. There may be additional risks that neither SPAC nor the Company presently know or that SPAC and the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's and SPAC's assessment as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Disclaimer (Cont'd)

Industry and Market Data

This Presentation also contains information, estimates and other statistical data derived from third party sources (including Frost & Sullivan). Such information involves a number of assumptions and limitations and due to the nature of the techniques and methodologies used in market research, and Frost & Sullivan cannot guarantee the accuracy of such information. You are cautioned not to give undue weight on such estimates. Neither SPAC nor the Company has independently verified such third party information, and makes no representation, express or implied, as to the accuracy, completeness, timeliness, reliability or availability of such third party information. SPAC and the Company may have supplemented such information where necessary, taking into account publicly available information about other industry participants.

Use of Projections and Historical Financial Information

The 2019 and 2020 historical financial data included in this Presentation has been derived from Prenetics Limited's 2019 and 2020 financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") and are subject to updates based on an ongoing external audit in accordance with the Public Company Accounting Oversight Board standards. In addition, the Company's quarterly financial data included in this Presentation is based on financial data derived from the Company's management accounts that have not been reviewed or audited and are subject to further review and updates.

This Presentation contains financial forecasts for the Company with respect to certain financial results for the Company's fiscal years 2021 through 2025 for illustrative purposes. Neither SPAC's nor the Company's independent auditors have audited, studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections are forward-looking statements and should not be relied upon as being necessarily indicative of future results. In this Presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. While such information and projections are necessarily speculative, SPAC and the Company believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. All subsequent written and oral forward-looking statements concerning the Company and SPAC, the Transaction or other matters and attributable to the Company and SPAC or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

Non-IFRS Financial Measures

This Presentation also includes references to non-IFRS financial measures, such as the Company's Adjusted EBITDA for 2019 and 2020. Such non-IFRS measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with IFRS. SPAC and the Company believe these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. SPAC and the Company believe that the use of these non-IFRS financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing the Company's financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. Management does not consider these non-IFRS measures in isolation or as an alternative to financial measures determined in accordance with IFRS. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures.

Additionally, to the extent that forward-looking non-IFRS financial measures are provided, they are presented on a non-IFRS basis without reconciliations due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.

Disclaimer (Cont'd)

Additional Information

If the Transaction is pursued, SPAC will be required to file a preliminary and definitive proxy statement, which may include a registration statement, and other relevant documents with the SEC. You are urged to read the proxy statement/prospectus and any other relevant documents filed with the SEC when they become available because, among other things, they will contain updates to the financial, industry and other information herein as well as important information about SPAC, the Company and the Transaction. Shareholders will be able to obtain a free copy of the proxy statement (when filed), as well as other filings containing information about SPAC, the Company and the Transaction, without charge, at the SEC's website located at www.sec.gov.

Participants in the Solicitation

SPAC and the Company, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from SPAC's shareholders in connection with the Transaction. A list of the names of such directors and executive officers and information regarding their interests in the Transaction will be contained in the proxy statement when available. You may obtain free copies of the proxy statement as described in the preceding paragraph. The definitive proxy statement will be mailed to shareholders as of a record date to be established for voting on the Transaction when it becomes available.

Trademarks

This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM, © or ® symbols, but such references are not intended to indicate, in any way, that SPAC or the Company will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights.

Neither SPAC, the Company, nor any of their respective directors, officers, employees, affiliates, advisors, representatives or agents, make any representation or warranty of any kind, express or implied, as to the value that may be realized in connection with the Transaction, the legal, regulatory, tax, financial, accounting or other effects of the Transaction or the accuracy or completeness of the information contained in this Presentation, and none of them shall have any liability based on or arising from, in whole or in part, any information contained in, or omitted from, this Presentation or for any other written or oral communication transmitted to any person or entity in the course of its evaluation of the Transaction, and they expressly disclaim any responsibility or liability for direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including lost income or profits and opportunity costs) in connection with the use of the information herein.

By accepting this Presentation, the recipient will be deemed to have acknowledge and agreed to the foregoing.



Presenters



Ben Cheng

Chief Executive Officer

ARTISAN
ACQUISITION CORP.



Danny Yeung

CEO & Co-Founder

Prenetics™



Stephen Lo, CPA, CFA

Chief Financial Officer

Prenetics™

Prenetics™

Adrian Cheng Led Team Backed by Inspirational Independent Directors



| | |
|--|---|
| <div style="text-align: center;">  <p>Dr. Adrian Cheng Founder of Artisan Acquisition Corp.</p>  </div> <div style="text-align: center; margin-top: 20px;">  <p>William Keller Independent Director</p>  </div> <div style="text-align: center; margin-top: 20px;">  <p>Frank Yu Independent Director</p>  </div> | <div style="text-align: center;">  <p>Ben Cheng Chief Executive Officer of Artisan Acquisition Corp.</p>  </div> <div style="text-align: center; margin-top: 20px;">  <p>Mitch Garber, C.M. Independent Director</p>  </div> <div style="text-align: center; margin-top: 20px;">  <p>Sean O'Neill Independent Director</p>  </div> |
|--|---|

5

Prenetics®

Prenetics is a Clear Fit for Artisan Acquisition Corp.

Target Criteria – Clearly Met by Prenetics

- ☑ Focus on disruptive lifestyle technologies in healthcare, consumer, technology
- ☑ Strong fundamentals with significant value creation opportunities
- ☑ Well-positioned to deliver value and synergies in the group's global cultural ecosystem
- ☑ Growth upsides through tapping global consumers' unmet demands & burgeoning markets

Prenetics
Investment Thesis for
ARTISAN
ACQUISITION CORP

- 1 **Disrupting & decentralizing** global healthcare with large global opportunity of over **US\$1.3trn¹**
- 2 **Strong R&D and product innovation capabilities** backed by experienced in-house team, strategic collaboration with Oxford University and vibrant **scientific ecosystem**
- 3 **First-mover advantage** in target geographies with **robust product pipeline** and **high growth potential**; well positioned to replicate U.S. success stories in its target geographies
- 4 **Inspirational founder** backed by **strong leadership team** of tech, biotech, healthcare and consumer veterans
- 5 **Strong financial profile** and **highly attractive expected valuation** relative to peers

Prenetics

6

Source: Frost & Sullivan.

Notes: 1. Global opportunity as of 2030; represents global market sizes and target addressable markets, except for colorectal cancer screening which does not include mainland China.

Significant Synergies - Prenetics and Adrian Cheng's Ecosystem

Significant Synergies

- Healthcare channel and user access
- Broad network of locations covering healthcare, retail, hospitality and other sectors
- Extensive customer, user, and fan base across platforms
- Direct corporate use cases across eco-system



7



PRENETICS

Decentralizing Healthcare

Prevention


Consumer genetic testing and early colorectal cancer screening

Global Opportunity: **US\$117 Billion+¹**

Personalized Care

Personalized nutrition, hair & sexual health products

Global opportunity: **US\$376 Billion+²**



○ Existing Products ○ Future Products

Diagnostics

Covid-19 testing, POCT / At-home diagnostic testing and medical genetic testing


Global opportunity: **US\$848 Billion+³**

9

Source: Frost & Sullivan.


Notes: Global opportunity as of 2030. 1. Represents global target addressable market for early colorectal cancer screening (except for mainland China) and global market size for consumer genetic testing. 2. Represents global target addressable market for hair loss and erectile dysfunction and global market size for personalized nutrition. 3. Represents global market size for medical device. 4. Represents each business segment revenue as % of total revenue expected in 2025.

Prenetics™



10

Prenetics™ Competitive Moat



Notes: 1. By testing volume and TrustPilot Review. 2. Include CircleDNA and Covid-19 tests; as of August 31, 2021.

Strategic R&D Collaboration with Oxford University

OSCAR – Oxford Suzhou Centre for Advanced Research

- Key research directly with the only overseas research centre by Oxford
- Initial focus will be on
 - a) HealthPod general development
 - b) HealthPod for Clinicians development



Prenetics Molecular Diagnostics Research Center at Oxford University

- Combined research with Oxford University enables Prenetics to have its own research centre at Oxford University
- Prenetics R&D team already works closely with Oxford team of Professors, with collaboration further enabling us to commercialize novel inventions
- Prenetics' ROFR to acquire technology / IP

Oxford University 3-Year Research Grant

- Key research directly with Oxford and the team of professors from Mar 2021
- Initial focus:
 - a) Improving sensitivity and time to results of Covid-19 reagent
 - b) Development of enzymes to lower cost
 - c) Assay development (e.g. Infectious disease, STD)



11 Dame Caroline Wilson (British ambassador to China) at OSCAR opening – June 2021

Close Collaboration with Prenetics In-house R&D Teams

| | |
|--|---|
|  <p>Dr. Lawrence Tzang, Ph.D. Co-founder & Chief Science Officer Scientific & Laboratory team</p> |  <p>Dr. Senthil Sundaram, M.D. Chief Clinical Officer Clinical & Bioinformatician team</p> |
|  <p>Dr. Mike Ma, Ph.D. Head of Clinical R&D Clinical R&D team</p> |  <p>Dr. Peter Wong, DPhil Chief Technology Officer Engineering & Development team</p> |
|  <p>Frank Ong, MD Chief Medical Officer Circle Snapshot R&D & Setup</p> | |



World-class Leadership Team of Tech, Biotech, and Healthcare Pioneers

Management Team



Danny Yeung
CEO & Co-Founder



Stephen Lo, CPA, CFA
Chief Financial Officer



Lawrence Tzang, PhD
Chief Scientific Officer &
Co-Founder



Avi Lasarow
CEO – EMEA



Mike Ma, PhD
Head of Clinical R&D



Frank Ong, MD
Chief Medical Officer



Key Scientific Advisers



Prof. Zhanfeng Cui
Donald Pollock Professor of
Chemical Engineering,
University of Oxford



Prof. Wei Huang
Associate Professor in
Dept. of Engineering Science,
University of Oxford



Dr. Monique Andersson
Medical Advisor, Director of Microbiology,
Oxford University Hospitals,
NHS Foundation Trusts



Prof. Michael Yang
Chair Professor of Biomedical
Sciences, Vice-President (R&D)
City University of Hong Kong





Prenetics Current Product Portfolio



Prevention



Leading Brand

In Asia and UK consumer genomics

50-100x

More data than the competitors

120k+

CircleDNA tests delivered since July 2019 launch

\$16bn+

Global Market Size¹

\$19mm

2021E CircleDNA Projected Revenue

34%

2020A-2025E Revenue CAGR

CircleDNA
The World's Most Comprehensive Consumer DNA Test


Source: Frost & Sullivan. Notes: 1. Global market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

CircleDNA – An All-New Industry Standard in Genetic Testing

Genotyping Technology

- **High false negative rate:** Will miss >90% mutations associated with cancer and disease
- **Pre-defined** and specific SNP Readings
- **Limited Data**, can only resolve single letter “typos”
- **Static**, will need to test again as science evolves

DNA Data Points



Our Next Generation - Whole Exome Technology

- Read protein-coding genes
- Clinical-grade consumer testing
- 50-100x more data over genotyping
- One test, a Lifetime of Value
- Identify >90% mutations associated with cancer and disease

15

Source: Company Website, Company Filings.

Prenetics™



CircleDNA – the Forefront of Health Diagnostics & Disease Prevention Covering Screening, Wellness, Proactive and Preventive Measures


500+ Reports Discovered Across 20 Categories

Family Planning & Disease
375 reports


Diet, Wellness, Lifestyle
69 reports

Traits
70 reports

16



A Snapshot of CircleDNA Tests



Prenetics

CircleDNA Product Offering



Vital

- 14 Categories - 125 Reports
- Diet, Nutrition, Fitness, Stress, Ancestry, Skin, and More
- 30 Mins Phone Consultation

Retail Price

USD 189

17



Family Planning

- 1 Category - 163 Reports
- Carrier Screening of recessive genetic diseases
- 30 Mins Phone Consultation

USD 499



Health

- 4 Categories - 115 Reports
- Cancer, Common Health Risks, Disease Risks, Dementia & Brain Health
- 30 Mins Phone Consultation

USD 499



Premium

- 20 Categories - 500+ Reports
- Vital + Family Planning + Health Bundle + Drug Response
- 30 Mins Phone Consultation (2x)

USD 629

Prenetics®

CircleDNA Marketing Strategy

Celebrity Ambassadors



Van Ness Wu
Actor & singer

15M+
social media followers



G.E.M.
Asia's Taylor Swift

50M+
social media followers



Gigi Leung
Actor, singer & mother

20M+
social media followers

ATL Marketing



TRAM



WATSONS



TAXI



BILLBOARD

Social Media




Prenetics

CircleDNA – Extraordinary Growth with Significant Runway

Forecasted Growth Trajectory after Launch¹

(# of Cumulative Tests Sold, '000)



Market Size⁴

US\$8.8 bn

APAC / EMEA
Consumer DNA Test

Market Size⁴

US\$5.1 bn

US Consumer DNA Test

CircleDNA Revenue

(US\$ millions)



19

Source: Frost & Sullivan, Trust Pilot Review.

Notes: 1. Blue dotted line denotes management forecast; grey dotted line is extrapolation of 23andMe. 2. Market data as of August 31, 2021. 3. As of July 12, 2021.

4. Market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

Prenetics

Diagnostics



Prenetics laboratory inside Hong Kong International Airport

5M+
Covid-19 Molecular Test Performed

8 Labs
6 Airports in HK & UK, and 2 main labs

\$32bn+
Global Market Size¹

\$51mm
2020A Covid-19 Testing Revenue

77%
2020A-2022E Revenue CAGR

Blue Chip
Clientele of Governments & Corporates

Project Screen Covid-19 Testing

Source: Frost & Sullivan.

Notes: 1. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.

Prenetics Response To Covid-19

Key Highlights

HK Government

- **~2M tests** serviced for HK government as of 1Q 2021
- ✓ Community Testing
- ✓ Hospital Authority
- ✓ Department of Health
- ✓ Food and Environmental Hygiene Department (FEHD)



English Premier League

- Provides testing service up to **3,000 players and club staffs** for English Premier League on a regular basis



Airport Testing to International & Local Airports

- Airport testing in Hong Kong and the United Kingdom, including **HKIA¹, Heathrow, Manchester, Stansted, Luton, and Gatwick airports**
- Converted smoking lounge to an ISO-15189 **laboratory at the HKIA¹**. Prenetics is the **only** Covid-19 testing provider with **operating lab in HKIA¹**



Extensive Partnerships Across Sectors

Prenetics + Virgin Atlantic

- **Prenetics has become Virgin Atlantic's preferred at-home testing provider**, with customers able to order a complete end-to-end travel testing bundle, tailored to their destination

21

Note: 1. Hong Kong International Airport.

Travel (2022E Revenue \$89M)

Virgin Atlantic, Carnival Cruise Line, Cruise line operation of an entertainment company, Hong Kong International Airport, Heathrow Airport, London Luton Airport, London Stansted Airport, Manchester Airport, Gatwick Airport


Entertainment & Sports (2022E Revenue \$15M)

English Premier League, Professional Darts Corporation, England and Wales Cricket Board, British Academy Film Awards, Sky TV, Global Media & Entertainment Company, American Film & TV Studio

Prenetics[®]

Significant Upside as Travel “Resumes”

Covid-19 Testing Revenue Breakdown (US\$ millions)



\$32bn+
Global Market Size³

22 Source: Frost & Sullivan. Notes: 1. 2020 financials based on management accounts – excludes airline & cruises revenue in EMEA as breakdown is not available. 2. Include entertainment & sports, community testing & screening, corporate B2B testing, etc. 3. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.



Major COVID-19 Testing Technologies Comparison

| | Nucleic Acid Amplification (RT-LAMP) | Nucleic Acid Amplification Test (RT-PCR) | Antigen Test (Proteins) |
|---------------------------|--|--|--|
| Speed | ✓ Reaction time: 15 - 20min | ✗ Reaction time: 4 - 6 Hours | ✓ Reaction time: 15 - 30min |
| Accuracy | ✓ Higher: 96% | ✓ Highest: 99% | ✗ Symptomatic: 90% or above Asymptomatic: 27% |
| Mobility & Lab Required | ✓ No Need Laboratory No Lab Technicians | ✗ Need Laboratory Lab Technicians | ✓ No Need Laboratory No Lab Technicians |
| Availability | ✓ Yes | ✓ Yes | ✓ Yes |
| Use-Case | ✓ Symptomatic & Asymptomatic | ✓ Symptomatic & Asymptomatic | ✗ Symptomatic (7 days of infection) |
| Through-put & Scalability | ✓ Highly Scalable | ✗ Not scalable | ✓ Highly Scalable |

23 Source: Frost & Sullivan.

PCR-Quality Technology from Oxford

Prenetics


Game Changing POC / At-Home PCR-Quality Testing Technology from Oxford University



Approvals / Recognitions

- ✓ MHRA¹ in UK
- ✓ CE IVD² in EU
- US FDA in process; Expected by 2021Q4 / 2022Q1

CNN Inside Oxford Lab Developing 30-minute Coronavirus Test



24 Notes: 1. Medicines and Healthcare products Regulatory Agency. 2. Approved CE Marketing on In-Vitro Diagnostic medical devices.

Prenetics™

Circle HealthPod

Rapid Detection System
For Covid-19

Source: Company Website. Please view Circle HealthPod Product video here: <https://circlepod.co/>.

Diagnostics



Detects Covid-19 with **PCR-Quality Technology**



Future Assays:

- Influenza / Flu
- STDs

20min

Time to result

96% / 99.9%²

Sensitivity / Specificity

\$848bn+

Global Market Size¹

Mobile & Scalable

No lab or specialist equipment

Painless

Pain-free nasal swab

CE-IVD Marked

Expect to receive US FDA EUA by Q1 2022

Circle HealthPod A Lab. In Your Pocket

Launched in Hong Kong To launch in EU, Southeast Asia and the US

Source: Frost & Sullivan. Notes: 1. Represents global market size for medical device based on the projection for 2030. 2. According to trials done at University of Oxford when compared to PCR.

Successful Commercialization Case Study: Cue Health

The Cue Health Monitoring System

- The Cue Health Monitoring System is a fast, compact, highly portable testing platform with high performance and accuracy, utilizing molecular diagnostic technology
- Cue Health's COVID-19 cartridge test is authorized by the US FDA for home use with no prescription in Mar 2021. The company filed for a US IPO on September 1, 2021.

Cue Health awarded \$481 million to scale up production of COVID-19 test: HHS



REUTERS



HHS launches pilot program in five states using rapid Covid test deployed by NBA



Go-to-Market Strategy: Key Partners & Target Clients

Public Sector
US Department of Defense
Government Agencies

Enterprise
Henry Schein
Fortune 500 Companies

Healthcare Provider
Mayo Clinic
Hospitals / Private Clinics

Direct-to-Consumer
E-commerce
In-store

27

Source: Company Filings, Cue Health Company Website, Bloomberg, Reuters, CNBC.
Notes: 1. Per Bloomberg, as of December 2020.

Prenetics

Use Case



Private Use

- At-home testing
- On the go testing (with portable charger)



Hospitals & Clinics

- In-patient and out-patient on-site screening
- Regular testing for healthcare workers & family



Hotels & Apartments

- For hotel guests as a complimentary item for their stay or as a paid in-room service
- Must-have for every homes to for a peace of mind



Schools

- Rapid testing for schools
- Regular testing for students and teachers



NGO Community Screen

- Easy and simple test for NGO's
- Regular testing for community members




Sports & Entertainment

- Rapid at-home testing for attendees
- Regular testing for players and staffs

28

Prenetics

Illustrative Representation of Diagnostic-testing Supply Chain



Circle HealthPod B2B Stations

Multiple Circle HealthPods

Circle HealthPod Dashboard

Partners App

Single use Specimen Capsule

Preneetics

| Type of test | Date | Test Result |
|---------------|---------------------|-------------|
| Covid-19 Test | May 24, 2020, 18:18 | Positive |
| Covid-19 Test | May 20, 2020, 20:32 | Invalid |
| Covid-19 Test | May 19, 2020, 18:53 | Positive |
| Covid-19 Test | May 12, 2020, 10:18 | Positive |
| Covid-19 Test | May 08, 2020, 23:19 | Positive |
| Covid-19 Test | May 02, 2020, 16:46 | Positive |

30

Circle HealthPod Marketing Strategy – Partnering with International Actor Donnie Yen on Extensive ATL Marketing Campaigns



31

Notes: Initial marketing campaign focusing only for Hong Kong market.

Prenetics®



Imminent Product Launches



Prevention



ColoClear

The Only Non-Invasive Colon Cancer Screening Test Approved by NMPA

Source: Frost & Sullivan.

Notes: 1. Global target addressable market for colorectal cancer screening based on projection for 2030, except for mainland China; target population is the age group of 40-74 years old.

96%

Sensitivity -
Highly Accurate

Cost Effective

Comparing to
Colonoscopy

Successful Model

Comparable to
ColoGuard
in the US


\$101bn+

Addressable
market¹


Launching in Q1 2022E

Significant Whitespace in Asia Markets Presents Attractive Growth Opportunities

Colorectal Cancer Screening Market in US (2019)



Colorectal Cancer Screening Market in HK & SEA (2019)



Revenue of ColoGuard for Exact Sciences¹ (US\$ mm)



Projected Revenue of ColoClear for Prenetics (US\$ mm)




34

Source: Frost & Sullivan.

Notes: 1. Before Exact Science's acquisition of Genomic Health in November 2019, ColoGuard is the only major revenue source for Exact Sciences. 2. Market data as of August 31, 2021.

Prenetics

Strategic Technology Transfer from New Horizon to Launch ColoClear



Establishment of Strategic Partnership with New Horizon Health to Commercialize ColoClear

35

Source: Company Filings. Notes: USD/HKD FX rate of 7.78. 1. Market data as of August 31, 2021. 2. Including Singapore, Malaysia, Indonesia, Vietnam, Philippines and Thailand. 3. Gross profit = Gross Revenue - COGS for products sold - COGS for lab testing services - Sales & Marketing Expenses (including sales incentives and logistics costs).

Prenetics™

ColoClear – Industry Leading Performance

FIT-DNA has higher sensitivity when comparing with other non-invasive Colon Cancer screening tests.

| Non-Invasive Tests | Sensitivity | | Specificity | Detection limitations | Sample size needed | Dietary restrictions |
|---|-------------|------------|-------------|--|----------------------|----------------------|
| | CRC | AA | | | | |
| gFOBT (Hemoccult II) | 40% | 12% | 98% | Intermittent bleeding | 3 bowel movements | Yes |
| FIT (Faecal Immunochemical Test) | 70% | 22% | 95% | Intermittent bleeding | Single sample | No |
| ENACT SCIENCES FIT-DNA (ColoGuard) | 92% | 65% | 92% | CRC and AA continuously exfoliate cells | Single sample | No |
| Prenetics FIT-DNA (ColoClear) | 96% | 64% | 87% | CRC and AA continuously exfoliate cells | Single sample | No |

| Diagnostic Invasive Test | Sensitivity | | Specificity |
|--------------------------|----------------|------------|-------------|
| | CRC | AA | |
| Colonoscopy | >95% | 95% | 90% |

✓ Closest CRC sensitivity to actual colonoscopy standards

Sensitivity = True positive / (True positive + False negative) * 100%;
 Specificity = True negative / (True negative + False negative) * 100%.

36

Source: Company filings, Colorectal cancer development and advances in screening, Clin Interv Aging. 2016 July 19; 967-976.

Prenetics®



New Launches Beyond 2022



Diagnostics



50+

 Wide Range of Tests for Everyone

Painless

 Blood collection at home

Digital Health Platform

 Track your Health Progress

Successful Model

 Comparable to Everlywell, Letsgetchecked

\$6bn+

 Global Market Size¹

Circle SnapShot

Your annual health check at home

Launching in Q1 2022E

Source: Frost & Sullivan.

Notes: 1. Global market size for at-home health testing based on projection for 2030; does not include home testing kits which do not require lab tests; Covid-19 at-home test has not been considered.

Successful Commercialization Case Study: Everlywell

Innovative at-home Health Testing

- Everlywell's portfolio of 30+ at-home tests offer simple sample collection and physician-reviewed results and insights sent to your device in 5 to 7 business days
- In March 2021, Everlywell announced its acquisition of PWNHealth and Home Access Health Corp. in a cash and stock deal. The combined companies, re-branded as Everly Health, expects to support more than 20 million people annually in the US



Popular Everlywell Tests

Food Sensitivity

Measure body's immune systems' IgC antibody reactivity to 96 foods



Metabolism

Measure free testosterone, cortisol and TSH levels



Indoor & Outdoor Allergy

Test for 40 common indoor and outdoor allergens



Sexually Transmitted Disease

Screens for 7 common sexually transmitted infections



39

Source: Everlywell Company Website, Bloomberg.
Notes: 1. Per Bloomberg news article, as of March 2021.

Prenetics®

Diagnostics



Circle Medical Genetic Testing for Physicians

Source: Frost & Sullivan.

Notes: 1. Global market size for clinical molecular test service based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

20+
Wide range of tests for everyone





Next Generation Sequencing
Advanced Technology

Successful Model
Comparable to Invitae, Natera

\$59bn+
Global Market Size¹

Launching in Q1 2023E

Significant Growth Potential in Asia / Europe Markets Present Attractive Growth Opportunities



41

Source: Frost & Sullivan.

Notes: 1. Billable volume for 2018 – 2019. Accessioned volume for 2017. 2. Market data as of August 31, 2021. 3. While its geographic scope is not limited to certain regions, it is expected to predominantly generate revenue in Hong Kong, SE Asia and Europe during the projection period.

Prenetics™

Personalized Care



Data-based

Personalized solution based on data analytics

63%

of CircleDNA customers want Circle One¹

Recurring Revenue

Subscription model

Cross Selling

Leverage existing CircleDNA customer base

\$376bn+

Addressable market²

Circle One / F1x / Fem Testing into personalized care

Launching in 2022E-2023E

Source: Frost & Sullivan.

Notes: 1. Based on CircleDNA customer survey conducted in Feb 2020. 2. Represents global target addressable market for hair loss and erectile dysfunction and global market size for personalized nutrition based on projection for 2030.

Successful Commercialization Case Study: Roman

Roman – Digital Health Clinic for Men

- Roman provides personalized solutions to men for the treatment of erectile dysfunction, hair loss, premature ejaculation, etc.
- Roman’s daily vitamins and supplements are available in 4,600+ Walmart stores across the United States



Bloomberg

Online Pharmacy Ro Is Said to Raise Funds at \$5 Billion Value

Online pharmacy and health technology company Ro has raised \$500 million in new funding, its chief executive officer told Bloomberg News.

FORTUNE

Telehealth startup Ro partners with Pfizer to give its ED business a boost

Key Partners

Sports & Entertainments

MLB

Pharmaceuticals

Pfizer
Greenstone

Retailers

Walmart

Healthcare

Ribbon Health
Quest Diagnostics

Prenetics

43


Source: Roman Company Website, Bloomberg, PR Newswire, Fortune.
Notes: 1. Per Bloomberg, as of March 2021. Represents the post-money valuation of Ro, the operator of Roman.
2. Per Bloomberg, as of March 2021. Represents the lifetime fundraising of Ro, the operator of Roman.




Our Way Forward



Product Pipeline Built on a Robust Existing Foundation




Prenetics Delivering Favorable Metrics vs. US Peers 5 Years Ago



Notes: USD/HKD FX rate of 7.78. 1. 2021-2025 financials based on management forecast. Exact Sciences, Invitae and Natera historical financials sourced from company filings. 2. Indicates primary product focus. 3. Please refer to Transaction Summary page for further details. 4. Market data as of December 31, 2016. 5. Market data as of August 31, 2021.



Tremendous Value Potential for Prenetics to be Unlocked via Synergistic Acquisitions



47

Notes: 1. Market data as of December 31, 2016. 2. Market data as of July 12, 2021. 3. Please refer to Transaction Summary page for further details.

Prenetics™




Financial Information



Prenetics Continues To Transform Itself, Now At An Incredible Rate

Revenue Evolution¹




49 Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.
 1. 2019 and 2020 financials based on audited accounts – Prevention segment revenue includes other service fees and adjustments. 2021 and 2025 financials based on management forecast.



Driven by Robust Organic Growth and Product Launch Strategies

Revenue in US\$ millions

Product Launch Year



50


Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.
 1. 2019 and 2020 financials based on audited accounts – Prevention segment revenue includes other service fees and adjustments. 2021-2025 financials based on management forecast.

Prenetics®

COVID-19: An Opportunity to Better Reimagine Healthcare

Revenue in US\$ millions¹

We conservatively assumed COVID-19 testing market is not here to stay. Instead, it has allowed us the opportunity to build the tools and expand our platform in order to better serve the new world order of healthcare



- Testing the New Norm
- Self Care a Necessity
- New Technology
- Brand & Trust
- Network
- Time to Market

51

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.
 1. 2019 and 2020 financials based on audited accounts – Prevention segment revenue includes other service fees and adjustments. 2021-2025 financials based on management forecast.

Prenetics™

High Operating Efficiency Leading to High Growth

| Financials in US\$ million ¹ | 2019A | 2020A | 1Q21A | 2021E | 2022E | 2023E | 2024E | 2025E |
|--|--------|-------|-------|-------|-------|-------|-------|-------|
| Revenue | 9 | 65 | 57 | 205 | 272 | 307 | 429 | 640 |
| YoY % | NA | 606% | 1315% | 215% | 33% | 13% | 40% | 49% |
| Gross Profit ² | 3 | 27 | 22 | 85 | 118 | 137 | 185 | 295 |
| Gross Margin % | 33% | 41% | 39% | 41% | 43% | 45% | 43% | 46% |
| Sales & Marketing Expenses ² | 5 | 6 | 2 | 16 | 41 | 72 | 80 | 107 |
| Research & Development Expenses ² | 2 | 2 | 1 | 30 | 36 | 50 | 64 | 83 |
| Administrative and Other Expenses ^{2,3} | 9 | 14 | 6 | 19 | 27 | 36 | 48 | 65 |
| Adjusted EBITDA (Non-GAAP) | (12) | 4 | 12 | 21 | 14 | (21) | (7) | 39 |
| Adjusted EBITDA Margin % | (131%) | 7% | 21% | 10% | 5% | (7%) | (2%) | 6% |
| Depreciation and Amortization | 2 | 2 | 1 | 8 | 13 | 17 | 20 | 21 |
| ESOP & Other Non-Operating Expenses ⁴ | 6 | 4 | 9 | 54 | 16 | 18 | 25 | 37 |
| Net Profit / (Loss) | (20) | (2) | 2 | (41) | (15) | (56) | (52) | (19) |
| Net Profit Margin % | (219%) | (3%) | 3% | (20%) | (6%) | (18%) | (12%) | (3%) |

- Revenue growth driven by robust organic expansion and product launch strategies

- Significant market opportunity in multiple verticals; Pipeline products expected to benefit from customer and operational synergies across platforms

- Significant positive momentum is expected from 2024 onwards as most products are in their high growth stage

52

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer. 1. 2019 and 2020 financials based on audited accounts. 2021-2025 financials based on management forecast. 2. Excludes depreciation and amortization expenses. 3. Profit sharing to New Horizon for ColoClear is also included. 4. Non-operating expenses primarily attributable to fair value adjustments for ESOP and convertible securities issued by the Company. Includes tax expense and tax credit.

Prenetics™

Prenetics™

Transaction Overview




Transaction Summary

Transaction Overview¹

- Illustrative enterprise value of \$1.25 billion
- Artisan Acquisition Corp. to merge with Prenetics
 - An implied multiple of 4.6x 2022E Revenue and 4.1x 2023E Revenue
- Concurrent with the transaction, \$60mm raised in the form of forward purchase agreements ("FPAs") from Aspek and PAG, in addition to another \$60mm raised in a PIPE from Lippo, Dragonstone, Xen Capital and others at \$10.00 per share
- 100% of Prenetics existing shareholders roll into the new entity. No existing shareholders are exiting
- Proceeds to be used for strategic acquisition or investments, R&D, product roll out, geographic expansion and general corporate purposes

Illustrative Ownership¹



Illustrative Enterprise Value¹

| | |
|--|----------------|
| Share Price | \$10.00 |
| Shares Outstanding (mm) | 170.92 |
| Illustrative Post-Money Equity Value | \$1,709 |
| (-) Net Cash to Balance Sheet ³ | \$455 |
| Illustrative Enterprise Value | \$1,254 |
| EV / 2022E Revenue | 4.6x |
| EV / 2023E Revenue | 4.1x |

Illustrative Sources & Uses

Assumes 0% redemption by SPAC Shareholders

| Sources | | Uses | |
|---|----------------|---|----------------|
| Existing Target Shareholder Equity Rollover | \$1,150 | Existing Target Shareholder Equity Rollover | \$1,150 |
| Sponsor Promote ⁴ | 100 | Sponsor Promote ⁴ | 100 |
| Cash Available in SPAC Trust Account | 339 | Transaction Expenses | 40 |
| Forward Purchase Agreement | 60 | Net Cash to Balance Sheet | 419 |
| PIPE | 60 | | |
| Total Sources | \$1,709 | Total Uses | \$1,709 |

Notes: USD/HKD FX rate of 7.78.

1. Excludes (i) the impact of any equity awards issued at or after the closing of the transaction, (ii) the dilutive impact of 18.7mm warrants (11.3mm SPAC public warrants, 5.9mm of sponsor warrants, 1.5mm of FPA warrants) with a strike price of \$11.50 per share, and (iii) the impact of shares with super-voting rights. Includes 9.98mm total Class B ordinary shares.

2. Includes SPAC directors.


3. Includes net cash to balance sheet of \$419mm post the transaction, and Prenetics balance sheet net cash of \$35.4mm, the pro-forma amount of which includes a cash balance of \$9.4mm as of 1Q 2021 and \$26.0mm of proceeds from pre-IPO fundraising.

4. Includes total 9.13mm Class B ordinary shares held by the Sponsor, 0.75mm Class B ordinary shares held by the FPA providers, and 0.1mm Class B ordinary shares held by SPAC directors.

54

Prenetics

Sum-of-the-Parts Valuation: Today



Notes: USD/HKD FX rate of 7.78. 1. Prenetics' 2023 net revenue, which takes into account GST and transaction costs, from the management forecast used to calculate the implied sum-of-the-parts valuation. 2. EV/CY2023E revenue calculated based on 2023E total net revenue including net revenue from Project Screen. 3. 23andMe, Invitae, Natera, Exact Sciences and New Horizon Health were referenced for EV/revenue multiples on Prenetics' prevention and personalized care business segment. 4. Autobio Diagnostics, Dr. Pal PathLabs, Invitae, Metropolis Healthcare and Qidel were referenced for EV/revenue multiples on Prenetics' diagnostics business segment. Project Screen business was not taken into account in the valuation of the diagnostics business given the phaseout of the business from 2022 onwards.



Peers' Proven Successes Supported by Substantial Valuation

| | Prenetics Products | Peers ¹ | Current Valuation / Market Capitalization ² |
|-------------------|---|---|--|
| Prevention |  |  | \$3.5bn ³ |
| |  |  | \$2.6bn ³ |
| Diagnostics |  |  | \$2.0bn ⁴ |
| |  |  | \$2.9bn ⁵ |
| |  |  | \$6.4bn ³ |
| Personalized Care |  |  | \$5.0bn ⁶ |

56

Source: Bloomberg. Notes: 1. Select companies with comparable products focused in the US / China. 2. Market cap for listed companies, or latest private round valuation. 3. Market cap as of August 31, 2021. 4. Valuation reportedly discussed in the latest private round; per Bloomberg, as of December 2020. 5. Valuation after the acquisition of PWNHealth; per Bloomberg, as of March 2021. 6. Post-money valuation for \$500mm fundraising; per Bloomberg, as of March 2021.

Prenetics[®]



Benchmarking Analysis

Prenetics



Prevention / Personalized Care

Diagnostics

EV / CY2022E Revenue Multiples



EV / CY2023E Revenue Multiples



57

Source: Company disclosures, broker reports and FactSet as of August 31, 2021.
 1. Prenetics' EV/revenue multiples are based on illustrative enterprise value of \$1.254bn



Select Precedent Transactions

| Date | Acquiror | Target | Public / Private | EV ¹ (US\$m) | EV/LTM | |
|--------|---------------------|----------------------------------|------------------|-------------------------|-----------|-----------------|
| | | | | | Sales (x) | EBITDA (x) |
| Apr-21 | CA HEALTHCARE | lumiraDx | Private | 3,000.0 | - | - |
| Apr-21 | DiaSorin Molecular | Luminex | Public | 1,624.3 | 3.9 | 22.3 |
| Mar-21 | Roche | GenMark Dx | Public | 1,729.0 | 10.1 | - |
| Feb-21 | VG REQUISITAS | 23andMe | Private | 3,500.0 | 11.5 | - |
| Oct-20 | EXACT SCIENCES | Thrive. Faster Diagnostics | Private | 1,700.0 | - | - |
| Oct-20 | EXACT SCIENCES | base | Private | 410.0 | - | - |
| Sep-20 | investor | ADVANCED INSTRUMENTS | Private | 780.0 | 10.8 | 24.1 |
| Sep-20 | QIAGEN | NeuMDx (80%) | Private | 309.6 | - | - |
| Jun-20 | INVITAE | ARCHER | Private | 886.0 | 17.7 | nm ² |
| Mar-20 | INVITAE | diploid | Private | 95.0 | - | - |
| Feb-20 | meridian BIOSCIENCE | Eyalenz Diagnostics Solutions | Public | 51.5 | 3.8 | nm ² |
| Jan-20 | NEO | HELEN HUNGATE (Oncology) | Private | 37.0 | 3.7 | - |
| | Mean | | | 1,343.5 | 8.8 | 23.2 |
| | Median | | | 833.0 | 10.1 | 23.2 |

58 Notes: Public filings, Dealogic and MergerMarket.
1. Excludes earnout. 2. EV / LTM EBITDA multiple less than 0.0x.

Prenetics



Appendix



Dysfunctional “Sick-care As Healthcare” Is Ripe for Disruption

Reactive Infrequent passive touch-points with healthcare system

Late Stage Focus Focused on treating already sick people

Vicious Cycle As more people get sick, they require more resources, leaving fewer resources to keep people healthy

Ageing Population & Chronic Disease Burden
Adding significant burden to healthcare system

6/10

of Global Population Lives with Two or More Chronic Diseases¹

1 / 4

Wastage in US Healthcare Spending²

US\$8.8trn

Global Healthcare Spending in 2021³


59%

% Relative Lifetime Healthcare Expenditure at Age 65 or Over⁴

Conventional Healthcare Is No Longer a Viable Solution

Sources & Notes: 1. Adults aged 65 or over in total 27 OECD countries as of 2014. OECD. 2. JAMA, <https://www.healthleadersmedia.com/clinical-care/wasteful-spending-us-healthcare-estimated-760-billion-935-billion>. 3. IHS Markit, <https://ihsmarkit.com/research-analysis/global-healthcare-spend-to-remain-stable.html>. 4. The Lifetime Distribution of Health Care Costs: Borhami Alemayehu, Kenneth E Warner, et al. (June 2004).

Asia Based, Global Presence




61 Note: 1. Operates through a joint venture.

Prenetics[®]

Key Milestones

● Corporate Events ● Fundraising



62 Note: Logos under each fundraising round represent the lead / key investors. 1. As of June 2021.




Circle SnapShot

Digital SnapShot of Your Health

SnapShot is a user-friendly results delivery system that capitalises on market trends and consumer expectations.


The device will work to analyse blood markers across health categories including, for example:



63

SnapShot is both an off-the-shelf and white-label solution (including API functionality) offering an E2E service.


This includes fulfilling the blood test kits, delivering to the customer including returns, processing of samples and release of results.



Prenetics®

Circle SnapShot

Illustrative SnapShot Tests – Planned Launching in 2022E







64

Circle Medical

Moving into Medical Genetic Testing (Circle Medical) – Launching in 2023E

Revealing the cause of genetic diseases | Targeted and symptoms-based diagnostic testing


| Single Gene Testing | Monogenic Panels | Exome Sequencing | Genome Sequencing |
|---|--|---|---|
|  |  |  |  |
| Rapid & Low-Cost 20 Genes | 15+ Specialities 500+ Panels | 1,000's of Rare Diseases | Most Comprehensive |
| BRCA1 BRCA2 APOE CYP2C19 CHEK2 FH | Oncology Reproductive Health Neurology Pediatrics Immunology Hematology | Confirm the diagnosis for complex or unclear symptoms Identify or rule out the mutation that causes the symptoms | 1,000's of Rare Diseases Point Mutations Structural Variants Complex Mutations Non-Coding Mutations Disease Susceptibility |

65

Prenetics[®]

Circle One / F1x / Fem

Personalized Health Products – Planned to start from 2022



66

Source: Frost & Sullivan.

1. Global market size for personalized nutrition based on projection for 2030. 2. Global target addressable market for hair loss and erectile dysfunction for 2030.

Prenetics[®]

Circle One / F1x / Fem

How It Works



120K+
Customer Data¹



31M
Genetic Data Points¹

67



**Combine Customer
and Genetic Data**



**Use Algorithm to
Process the Data**



**Personalized
Supplements**



**Unspoken
Needs Solutions**

Prenetics

Summary Financials

| Financials in US\$ million ¹ | 2019A | 2020A | 1Q20A | 1Q21A | 2021E | 2022E | 2023E | 2024E | 2025E |
|--|-------------|------------|------------|-----------|-------------|-------------|-------------|-------------|-------------|
| Prevention | 9 | 14 | 4 | 4 | 20 | 31 | 69 | 102 | 159 |
| - Circle DNA | NA | NA | NA | NA | 19 | 21 | 42 | 52 | 62 |
| - ColoClear | - | NA | NA | NA | 1 | 10 | 27 | 50 | 98 |
| - Others | NA | NA | NA | NA | - | - | - | - | - |
| Diagnostics | - | 51 | - | 54 | 185 | 236 | 215 | 290 | 434 |
| - Project Screen | - | 51 | - | 54 | 173 | 162 | 32 | 6 | - |
| - Circle HealthPod | - | - | - | - | 12 | 56 | 123 | 177 | 243 |
| - Circle SnapShot | - | - | - | - | - | 18 | 35 | 69 | 135 |
| - Circle Medical | - | - | - | - | - | - | 26 | 38 | 56 |
| Personalised Care | - | - | - | - | - | 4 | 23 | 37 | 47 |
| Revenue | 9 | 65 | 4 | 57 | 205 | 272 | 307 | 429 | 640 |
| Prevention ² | 3 | 5 | 2 | 1 | 9 | 16 | 38 | 57 | 88 |
| Diagnostics ² | - | 21 | (0) | 21 | 76 | 100 | 89 | 109 | 180 |
| Personalised Care ² | - | - | - | - | - | 2 | 11 | 19 | 26 |
| Gross Profit² | 3 | 27 | 2 | 22 | 85 | 118 | 137 | 185 | 295 |
| Total Marketing Expenses ² | 5 | 6 | 2 | 2 | 16 | 41 | 72 | 80 | 107 |
| Administrative Expenses ² | 9 | 14 | 2 | 6 | 19 | 27 | 36 | 48 | 65 |
| Research & Development Expenses ^{2,3} | 2 | 2 | 0 | 1 | 30 | 36 | 50 | 64 | 83 |
| Adjusted EBITDA | (12) | 4 | (2) | 12 | 21 | 14 | (21) | (7) | 39 |
| Depreciation and Amortization | 2 | 2 | 0 | 1 | 8 | 13 | 17 | 20 | 21 |
| Adjusted EBIT | (14) | 2 | (3) | 11 | 13 | 1 | (38) | (26) | 18 |
| Net interest expense | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Other expense / (income) | 0 | (0) | 0 | (1) | - | - | - | - | - |
| ESOP | 4 | 2 | 1 | 0 | 12 | 16 | 18 | 25 | 37 |
| Net Operating Profit / (Loss) | (18) | 1 | (4) | 11 | 1 | (15) | (56) | (52) | (19) |
| Other Non-Operating Expense | 3 | 5 | 0 | 7 | 41 | - | - | - | - |
| Profit / (Loss) before taxation | (21) | (4) | (4) | 4 | (41) | (15) | (56) | (52) | (19) |
| Income Tax / (Credit) | (1) | (2) | (3) | 2 | 0 | - | - | - | - |
| Net Profit / (Loss) | (20) | (2) | (1) | 2 | (41) | (15) | (56) | (52) | (19) |


68

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.

1. 2019 and 2020 financials based on audited accounts except by-product revenues which are based on management accounts. 2021-2025 financials based on management forecast.
2. Excludes depreciation and amortization expenses. 3. Profit sharing to New Horizon for ColoClear is also included.


Conservative Cash Management & CAPEX Planning

Cash Burn Rate in US\$ millions



- Cash burn rate (from operating and investing activities) averaging at US\$43 million per year in 21-25E
- Continuous R&D and product commercialization efforts help position company for growth and profitability in the long-term
- Strong fundraising track record to support the financing of company's business expansion plans

CAPEX in US\$ millions



- Large increase in CapEX expected from 22-24E to budget for IP acquisition in relation to R&D technology
- Expected decrease in CapEX as a percentage of revenue as new product offerings continue to mature

69

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.
 1. 2019 and 2020 financials based on audited accounts. 2021-2025 financials based on management forecast. 2. Others include acquisition of subsidiary and investment in joint venture / associate as recorded on cash flow statement.

Prenetics

Product Portfolio Summary

| Product | Launch Date | IP Ownership | Developed Product In-House | Distribution Exclusivity | Distribution Region ¹ | Distribution Timeline | Current Consumer Base |
|-------------------------|-------------|--|---|--------------------------|----------------------------------|-----------------------|---|
| Circle DNA | July 2019 | Yes | Yes | Yes | Asia, EMEA | In Distribution | 120k+ tests delivered since 2019 launch |
| ColoClear | 1Q 2022E | Technical transfer from New Horizon Health | No | Yes | SE Asia, HK, Taiwan, Macau | Q1 2022E | N/A |
| Project Screen | 2020 | Yes | Yes | Yes | HK, UK | In Distribution | ~4 million covid-19 molecular tests performed |
| Circle HealthPod | Q3 2021E | Yes | In collaboration with Oxford University | Yes | Asia, EMEA | Q3 2021E | N/A |
| Circle SnapShot | 1Q 2022E | Yes | Yes | Yes | Asia, EMEA | 1Q 2022E | N/A |
| Circle Medical | 1Q 2023E | Yes | Yes | Yes | Asia, EMEA | 1Q 2023E | N/A |
| Circle One | 2022-2023E | Yes | Yes | Yes | Asia, EMEA | Q4 2022E | N/A |

70

Source: Company Website, Company Filings.
Notes: 1. Excludes Mainland China.



Risks Related to Prenetics's Business and Industry

Risks Related to Diagnostic Testing/Personal Genetics Business

1. A significant portion of Prenetics's historical revenue were and near-term revenue will be generated from sales of its COVID-19 test kit and services, for which the demand may be substantially reduced with the production and widely administered use of an efficacious vaccine or treatment for COVID-19, and failure of Prenetics to launch other new products and expand its overall customer base would harm its business and results of operation.
2. The diagnostic testing market, particularly with respect to COVID-19 diagnostic tests, is highly competitive, and many of Prenetics's competitors are larger, better established and have greater financial and other resources.
3. The personal genetics market is highly competitive, and many of Prenetics's competitors are more established and have stronger marketing capabilities and greater financial resources, which presents an ongoing threat to the success of its personal genetics business.
4. Prenetics's near-term business strategy and R&D efforts are centered around POCT / at-home infectious disease testing, at-home blood-based routine health checks, and clinical genomics for which the market is new and rapidly developing, making it difficult to evaluate the future prospects of its business.
5. Prenetics's near-term success is highly dependent on the successful launch of Circle HealthPod and commercialization of its COVID-19 test kit in other jurisdictions, and these products may not attain market acceptance, meet customer demands or be successfully commercialized in all or any of these jurisdictions especially due to its limited operating experience in such jurisdictions, which could negatively impact its future prospects.
6. Prenetics relies on several third-party manufacturers for the manufacturing, quality-testing, assembly and shipping of its COVID-19 test kit and other products. Any variation or termination of existing arrangements may require changes to sub-manufacturing arrangements which may affect Prenetics's ability to sell and distribute its COVID-19 test kit and other products temporarily and may adversely affect its business.
7. Clinical trials necessary to support a future test kit submission will be expensive and may require the enrollment of large numbers of subjects, and suitable subjects may be difficult to identify and recruit. Delays or failures in Prenetics's clinical trials will prevent it from commercializing any modified or new test kits and will adversely affect its business, operating results and prospects.
8. If the third parties engaged by Prenetics to conduct clinical trials and to assist with pre-clinical development do not perform as contractually required or expected, Prenetics may not be able to obtain regulatory approval for or commercialize its products.
9. The initial use of Prenetics's test kits requires users to follow instructions, and not adhering to instructions may lead to negative outcomes, which could harm the user experience and customer perception of Prenetics's products.
10. If Prenetics's test kits, devices or services do not perform as expected, its reputation, business and operating results will suffer.
11. If Prenetics is not successful in leveraging its platform to develop and commercialize additional test kits or in enhancing features and services of existing product, its ability to expand its business and achieve its strategic objectives would be impaired.

Other Business Risks

1. Prenetics has incurred net losses since its inception and it anticipates that it will continue to incur losses for the foreseeable future, which could harm its future business prospects.
2. Prenetics is an early-stage company and has a limited operating history, which may make it difficult to evaluate its current business and predict its future performance.
3. Prenetics has a number of pipeline products that are currently in R&D phase, including Circle Medical, Circle SnapShot, future assays of Circle HealthPod, Circle One and F1X and Fem, and may not be successful in its efforts to development of marketable products. Any failure to develop these products or any delay in the development could adversely affect its revenues and results of operations.
4. Prenetics has a limited history introducing new products and services to its customers. The future prospects of its business may be harmed if its efforts to attract new customers and engage existing customers with enhanced products, including the anticipated launch of Circle HealthPod, a rapid POCT / at-home detection system for infectious diseases in August 2021, are unsuccessful.
5. Prenetics may not be able to achieve or maintain satisfactory pricing and margins, and its pricing strategies may not meet customers' price expectations, which could adversely affect its revenues and results of operations.
6. Prenetics has increased and expects to further expand the size of its organization, and it may experience difficulties in managing its growth. If Prenetics is unable to manage the anticipated growth of its business, its future revenue and operating results may be harmed.
7. Prenetics's partnership with certain celebrities and key opinion leaders and use of social media and email may adversely affect Prenetics's reputation.
8. Prenetics relies substantially on its research collaboration with Oxford University for development and commercialization of its POCT / at-home infectious disease testing products. If Oxford University is unable to achieve projected development milestones or produce any meaningful research results, or experiences delays in doing so, Prenetics may not be able to capitalize on its investment in the collaboration projects and its business may be adversely affected.
9. Prenetics relies on a limited number of suppliers for test kit materials and for manufacturing and performing services for CircleDNA customers and may not be able to find replacements or immediately transition to alternative suppliers, which could adversely affect its ability to meet customer demand.
10. The operating results of Prenetics may fluctuate significantly, which makes its future operating results difficult to predict and could cause its operating results to fall below expectations.
11. Prenetics's business significantly depends upon the strength of Prenetics's brands, including Prenetics, CircleDNA and DNAFit, and any harm to Prenetics's brands or reputation may materially and adversely affect its business and results of operations.
12. If Prenetics cannot provide quality technical and customer and user support, it could lose customers and its business and prospectus will suffer.
13. If Prenetics is unable to successfully expand its sales and marketing to match its growth, its business may be adversely affected.
14. Prenetics is highly dependent on its senior management team and key personnel, and its business and operating results could be harmed if it is unable to retain senior management and to attract and retain qualified personnel necessary for its success.
15. The sizes of the markets and forecasts of market growth for the demand of Prenetics's products and services are based on a number of complex assumptions and estimates, and may be inaccurate.

Risks Related to Prenetics's Business and Industry (Cont'd)

Other Business Risks (Cont'd)

16. Prenetics may need to raise additional funds to develop its platform, commercialize new products or expand its operations, and it may be unable to raise capital when needed or on acceptable terms.
17. Prenetics plans to enter new business areas, such as clinical genomics and personalized nutrition products, where Prenetics does not have any experience or has minimal experience. Prenetics would likely face competition from entities more familiar with those businesses, and Prenetics's efforts may not succeed.
18. Prenetics may engage in acquisitions, investments or strategic alliances in the future, which could require significant management attention and resources, and could negatively affect its business, financial condition and results of operations.
19. Prenetics may incur debt or assume contingent or other liabilities or dilute Prenetics's shareholders in connection with acquisitions or strategic alliances.
20. The United Kingdom's withdrawal from the European Union could have an adverse impact on Prenetics's business.
21. If Prenetics or its third-party collaborators experience any business disruptions, Prenetics's operations and financial condition could be seriously harmed.
22. If Prenetics or PubCo fails to implement and maintain an effective system of internal controls, PubCo may be unable to accurately report its results of operations, meet its reporting obligations or prevent fraud.
23. Any significant disruption in service on Prenetics's website, mobile applications, or in Prenetics's computer or logistics systems, whether due to a failure with Prenetics's information technology systems or that of a third-party vendor, could harm Prenetics's reputation and may result in a loss of customers.

Risks Related to Government Regulation

1. Prenetics's test kits and testing devices are subject to various regulatory guidelines and any identified deficiencies or quality issue in the components of the test kits and testing devices could result in product recalls and could harm its reputation, business and financial results.
2. Prenetics's business collects and processes a large amount of data including personal information, and Prenetics will face legal, reputational, and financial risks if Prenetics fails to protect its customers' data from security breaches or cyberattacks. Prenetics is also subject to various laws and regulations relating to privacy or the protection or transfer of data relating to individuals, and any change in such laws and regulations or any failure by Prenetics to comply with such laws and regulations could adversely affect Prenetics's business.
3. Prenetics's products and services are and will continue to be subject to extensive regulation, compliance of which could be costly and time-consuming or may cause unanticipated delays or prevent the receipt of the required approvals to offer Prenetics's products and services.
4. Prenetics plans to expand operations to various jurisdictions in which it does not currently operate or where Prenetics has limited operating experience and where Prenetics may be subject to increased regulatory risks and local competition. If Prenetics is unsuccessful in any efforts to expand internationally, its business may be harmed.


Risks Related to Intellectual Property and Legal Proceedings

1. Prenetics depends, and may depend in the future, on intellectual property licensed from third parties, such as license from New Horizon Health for development and commercialization of ColoClear, and the expiration of such intellectual property, or the failure of such third parties to maintain or protect such intellectual property, or the termination of the licenses or other agreements permitting Prenetics to use such intellectual property could result in the loss of significant rights, which would harm its business.
2. Adverse publicity about any investigation, litigation, regulatory or legal action against Prenetics or its senior management could harm its reputation and business.
3. Prenetics does not currently own any issued patents. If Prenetics is unable to obtain, maintain and protect its intellectual property rights and proprietary information or prevent third-parties from making unauthorized use of its technology, its business could be harmed.
4. Prenetics may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that Prenetics's employees have wrongfully used or disclosed alleged trade secrets of their former employers.
5. Prenetics may be involved in patent litigation or other intellectual property infringement claims or administrative proceedings with respect to intellectual property, which could result in substantial costs and expenses, substantial liability for damages and may disrupt its business and operations.
6. Patent terms may be inadequate to protect Prenetics's competitive position on its products and services for an adequate amount of time.
7. Prenetics may be subject to legal proceedings and litigation, which are costly to defend and could materially harm its business and results of operations.
8. Prenetics uses certain open-source technology in its business and may use other open-source technology in its business in the future. It may face claims from open-source licensors claiming ownership of, or demanding the release of, the technology and any other intellectual property that it developed using or derived from such open-source technology.
9. Prenetics has not commissioned a formal external freedom to operate analysis with respect to its products or product candidates, and Prenetics may not be aware of issued patents that a third-party might assert are infringed by Prenetics's current or future products, which could materially impair its ability to commercialize such products.

Transaction Structure


Reorganization Steps

Step 1




- New Cayman Listco and Merger Sub 1 are formed**
- Merger Sub 1 merges into Artisan SPAC
- Outstanding Artisan SPAC stock and warrants cancelled in exchange for New Listco stock and warrants
- Transaction is intended to qualify for Artisan SPAC security holders as a § 368(a)(1)(F) tax-free reorganization for U.S. federal income tax purposes

Step 2



- Listco forms Cayman Merger Sub 2
- Merger Sub 2 merges into Prenetics Group, with Prenetics Group surviving
- Outstanding Prenetics Group stock cancelled in exchange for Listco stock
- Share exchange is intended to qualify as tax-free for U.S. federal income tax purposes under § 368(a); may also qualify under § 351 depending on size of Prenetics shareholders' percentage ownership of Listco

Resultant Transaction



73

*For illustrative purpose, we assume new public parent will be Cayman companies.
 **New Listco is formed by a non-U.S. person (e.g. Target CEO), or otherwise satisfies the business contacts test.



